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Malaria in Nonimmune Travelers: A Synopsis of History, 
Symptoms, and Treatment in 160 Patients 
Tomas Jelinek, H.D. Nothdurft, and T. Loscher 
Background: With the current increase of international travel to  tropical endemic areas, the incidence of malaria being imported 
into nonendemic countries has increased significantly. Disagreement concerning malaria chemoprophylaxis and inadequate 
knowledge of malarious areas, morbidity, and pretravel advise has led to  confusion among both health professionals as well as 
travelers. Therefore, this study was conducted to investigate malaria imported into Germany by identifying the high-risk endemic 
areas, clinical presentations, and chemoprophylactic and therapeutic regimens related to reported cases. 
Methods: Between 1990 and 1993, the 160 nonimmune travelers, all German nationals or residents for more than 10 years, 
presenting to  our travel clinic wi th microscopically confirmed malaria were investigated. For each, the travel history, 
chemoprophylaxis used during travel, symptoms, pathological diagnosis, and treatment efficacy were analyzed. 
Results: Africa (73%). Asia (21%), and Central South America (6%) were the endemic countries visited by our patients, of whom 
only 3% used the chemoprophylaxis recommended for their destination. Plasmodium falciparum was the most common patho- 
gen, found in more than half of our patients, and t? vivax(29%), t? ovale (6%). t? malariae (6%). a mixed infection with Rfalciparurn 
and P vivax (3%) were also detected. All patients presented with fever and headaches, a majority with profuse night sweats, 
insomnia, arthralgias, and myalgias, and diarrhea and abdominal cramps were experienced in 13% and 8%. respectively. In 
falciparum malaria, a recrudescence was observed in all patients who received chloroquine only, whereas quinine, halofantrine, 
and mefloquine were highly effective. In vivax malaria, a relapse rate of 14% was noted in the patients treated with the currently 
recommended regimen of chloroquine and primaquine. 
Conclusions: Visitors to endemic countries, especially to  Africa, are of significant risk. Given the l ow  compliance rate of 
chemoprophylaxis, a high percentage of malaria in our patients could have been avoided by an appropriate prophylaxis regimen 
and optimal pretravel counseling. (J  Travel Med  1:199-202. 1994) 
Malaria presents a serious hazard to travelers to 
endemic areas. As international air travel to tropical 
destinations becomes more and more popular, an in- 
crease in imported cases has been observed in 
nonendemic countries in recent year~. l -~ The impor- 
tance of appropriate drug prophylaxis has been 
stressed Chemoprophylaxis should be 
adapted to each traveler’s individual characteristics, 
the travel itinerary, and the drugs used.8 The risk of 
malaria infection varies depending on the destination 
and the exposure to infected mosquitos. Therefore, a 
profound knowledge of malarious areas and the fre- 
quency of infection acquired by nonimmune travelers 
is necessary when advice about prophylaxis is given 
by a physician. There is some disagreement about 
malaria drug prophylaxis for travelers to endemic re- 
g i o n ~ . ~  This leads to considerable diversity in the rec- 
ommended drug regimens used and in confusion 
among both health professionals and travelers. 
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In this study, a total of 160 patients who presented 
with imported malaria were investigated. The objec- 
tive of the investigation was to optimize counseling 
concerning malaria and also to obtain more informa- 
tion about malaria imported to Germany. The inten- 
tion was to identify areas with high risk for malaria 
infection for travelers, common clinical presentations, 
and the use of prophylactic and therapeutic regimens. 
Patients and Methods 
Twenty percent of the total patient population of 
the travel clinic under investigation present with fe- 
ver. Malaria is diagnosed in approximately 3% of the 
cases, with fever providing the guiding symptom. The 
case histories, symptoms, and treatment of 160 pa- 
tients with microscopically confirmed malaria, who 
were treated in our travel clinic during the period from 
1990 to 1993, were investigated. A thorough travel 
history was stressed as was knowledge of prophylac- 
tic antimalarial drugs used during the journey. A close 
follow up to detect any relapses was also stressed. 
Results 
All patients were German nationals or had been 
residents of Germany for more than 10 years. One 
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Figure 1 Malaria in nonimmune travelers: geographic distribution in 160 patients. 
hundred and sixteen (73 %) of the patients were male 
and 44 (28%) were female. Ages varied between 15 
months and 70 years (mean value 34.5 years, median 
32 years). The duration of travel varied from short 
journeys of 6 days to lengthy stays of up to 19 years 
(median 28 days). In 88 ( S ~ ' % O )  of the patients, a diag- 
nosis offalciparum malaria was established, 47 (29%) 
had vivax malaria, 10 (6%)  ovule malaria, 10 (6%)  
quartan malaria and 5 (3%) a mixed infection of 
fakiparum and vivax malaria. Investigation of the 
countries where the infection was acquired, revealed 
an obvious predominance of African destinations, es- 
pecially for the infection with fakiparum malaria (Fig. 
1). Thirty-four percent (confidence interval (95%): 31- 
6.4%) of all malaria cases had previously been to West 
Africa, 23% (confidence interval (95%): 20.5-25.7%) 
to East Africa, 6% (confidence interval (95%): 3- 
8.3%) to Central Africa, 3% (confidence interval 
(95%): 0.4-5.8%) to Southern Africa and further 8% 
(confidence interval (95%): 5.5-10.9%) to Madagas- 
car. So altogether, Africa contributed 73% of all ma- 
laria patients compared to 21 % (confidence interval 
(95%): 18-23.3%) from Asia and 6% (confidence 
interval (95%): 3-8.3%) from the Americas. No 
falciparum malaria was acquired in South America, 
whereas 50% of the malaria cases from West Africa 
were infected with P. falciparum. 
In 100% of the patients, symptoms consisted of 
fever and headache and were usually accompanied by 
other complaints such as general weakness (94%), 
profuse sweating at night (91 %), insomnia (69%), 
arthralgia (590/), myalgias (56%), diarrhea (13%), 
and abdominal cramps (So/,). 
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Figure 2 Prophylactic regimen used by 160 travelers with 
malaria (%I. 
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The duration of symptoms before diagnosis was 
confirmed depended largely on the form of malaria 
acquired. In falciparum malaria, 81% of the patients 
were diagnosed in the first week and the other 19% 
within 2 weeks after onset of symptoms. In vivax 
malaria, diagnosis was established in only 64% of the 
patients within 2 weeks. In 5 patients (1 1 YO), it took 
between 7 and 61 months, with returning febrile at- 
tacks, before the diagnosis of vivax malaria was con- 
firmed. Patients with ovule or quartan malaria were, 
in 80% of the cases, diagnosed within 3 weeks, but it 
took between 2 and 6 months in 2 patients (20%) 
before diagnosis was established. 
The investigation of the type of chemoprophylaxis 
used revealed a high percentage of incomplete or in- 
sufficient regimens. Only 3% used the chemopro- 
phylaxis appropriate for the drug resistance situation 
of malaria parasites at their destination. Forty-seven 
percent of the patients used no prophylactic regimen 
at all, and 8 %  carried a standby medication only. 
Chloroquine was used by 60 (38%) of the 160 inves- 
tigated patients as the prophylactic drug of choice. 
However, 37% of patients using chloroquine disrupted 
the intake regimen at some point of their journey 
(Fig. 2). 
Twenty six percent of patients had been treated 
prior to referral to our clinic. This had led to 17 dif- 
ferent drugs and drug combinations being used for 
therapy. All patients with falciparum malaria, who 
received chloroquine only, showed a recrudescence 
within 2-8 days (mean 3.5 days), whereas treatment 
with quinine presented with a curative efficacy of 
100%. Halofantrine and mefloquine were effective in 
94% and 98% of cases, respectively. A high relapse 
rate was common in patients infected with P. vivax, 
who were treated with combinations without prima- 
quine (100% in patients treated with halofantrine, 
mefloquine, or tetracycline; 75% in patients treated 
with chloroquine). These patients presented with re- 
lapses within 5 days and 4 months (mean 21 days). 
However, even in the 14% of patients treated with 
the usually recommended combination of chloroquine 
and primaquine: relapses did occur within 1 and 5 
months (mean 75 days). 
Discussion 
Although only 9% of our total patient popula- 
tion had been to West Africa prior to referral, 34% of 
the patients with malaria had acquired the infection 
there. Similar results were obtained for East Africa 
and Madagascar: 10 percent of our total patient popu- 
lation traveled to  these areas. Thirty-one percent of 
the patients with malaria had been previously to East 
Africa or Madagascar. The risk of acquiring malaria 
in South America and Southeast Asia seems lower. The 
figures here were 3% of the malaria-infected patients 
from a total of 9% of patients who traveled there. 
Twenty percent of all patients traveled to Southeast 
Asia, with only 9% becoming infected. Obviously, the 
risk of infection is highest in tropical Africa. These 
findings are comparable to  previous investigations: in 
these the risk of malaria infection per traveler was 
calculated at 1530 for tropical Africa, 1:1920 for In- 
dia, 1:4170 for Southeast Asia, 1:9090 for Central 
3% of all patients took drugs or drug combinations 
appropriate for the drug resistance situation of ma- 
laria parasites at the respective de~tination.~ Probably, 
a high percentage of the malaria cases discussed here 
could have been avoided by an appropriate malaria 
prophylaxis regimen. 
The duration of symptoms might be viewed as a 
measure of the diagnostic efficacy of the health pro- 
fessionals involved. All patients presented with clini- 
cal symptoms typical of malaria, mainly attacks of 
fever and headache. The diagnosis of falciparum ma- 
laria within the first week after onset of complaints in 
81% of the patients is certainly due to the usually se- 
vere symptoms in the presentation of this disease. The 
delay of up to 61 months in the diagnosis of vivax, 
ovule, and quartan malaria demonstrates the impor- 
tance of the consideration of malaria in the differen- 
tial diagnosis of fever, even if a journey to an endemic 
area took place several weeks ago. 
The failure rate in the different therapeutic regi- 
mens used is notable. Although the sample size is rather 
small, in some of the treatment groups, one clear re- 
sult is the demonstration of the inadequacy of 
chloroquine for the treatment of falciparum malaria 
acquired in Africa. Mainly for financial reasons, 
chloroquine is still the first line drug of choice in many 
developing countries. l 5  In semiimmune patients, 
chloroquine ameliorates the course of disease and 
might even result in clinical cure. In nonimmune pa- 
tients, however, the aim of malaria treatment must be 
to complete the eradication of the parasites, since even 
low parasitemias evoke clinical disease. All patients 
in this investigation treated with chloroquine only had 
already received therapy in Africa. Therefore, it is 
advisable to carry a potent antimalarial drug for emer- 
gency treatment when traveling to malarious coun- 
tries. Primaquine is highly effective in the prevention 
of relapses in vivax malaria as is demonstrated by the 
results in this study population. However, the relapse 
rate of 14.1% in patients treated with chloroquine 
and primaquine shows that relapses have to be ex- 
pected to a certain extent. 
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